BioWorld

Dec. 15, 2008

Exelixis Getting $195M Up Front in BMS Cancer Collaboration

Exelixis signed a major deal with Bristol-Myers Squibb Co., in which the drugmaker would pay a hefty $195 million up front for rights to cancer programs developed by Exelixis. (BioWorld Today) Read More

Daschle to Lead HHS, White House Health Reform Office

Momenta's Offering Adds $25M as FOBs Gain Momentum

BioPartnering: Learn How to Make the Right Moves

Vivus' Avanafil Starts Pivotal Testing in Erectile Dysfunction

Disappointing Memory Data Send Lexicon Shares Sliding

Other News To Note

Clinic Roundup

CTRC-AACR Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 9, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...